ICU Medical, Inc.

Valuation Analysis

About the Company

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irriga

ICU Medical, Inc. Stock at a Glance

ICU Medical, Inc. (ICUI) is currently trading at $142.20 with a market capitalization of $3.6B. The trailing P/E ratio stands at 76.45x, with a forward P/E of 15.24x. The 52-week range spans from $107.00 to $160.29; the current price is 11.3% below the yearly high. Year-over-year revenue growth stands at -12.3%. The net profit margin stands at 2.15%.

💰 Dividend

ICU Medical, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

7 analysts rate ICU Medical, Inc. (ICUI) on consensus: None. The average price target is $172.86, implying +21.56% from the current price. Analyst price targets range from $160.00 to $200.00.

ICU Medical, Inc.: The Investment Case in Detail

ICU Medical, Inc. (ICUI) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue is contracting at -12.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a net margin of just 2.15%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion.

Valuation in Context

With a PEG ratio of 0.08, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 15.24x is meaningfully below the trailing 76.45x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 21.56% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (8.81%).

Trading Data

Related Stocks in the Same Sector

Where can I buy ICU Medical, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.